Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Receivables (2022 - 2025)

Historic Receivables for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $674036.0.

  • 60 Degrees Pharmaceuticals' Receivables rose 10815.02% to $674036.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $674036.0, marking a year-over-year increase of 10815.02%. This contributed to the annual value of $486748.0 for FY2024, which is 11041.1% up from last year.
  • 60 Degrees Pharmaceuticals' Receivables amounted to $674036.0 in Q3 2025, which was up 10815.02% from $295034.0 recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Receivables' 5-year high stood at $674036.0 during Q3 2025, with a 5-year trough of $45965.0 in Q4 2022.
  • Its 4-year average for Receivables is $311022.6, with a median of $296370.0 in 2024.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 40327.86% in 2023, then plummeted by 45.08% in 2025.
  • 60 Degrees Pharmaceuticals' Receivables (Quarter) stood at $45965.0 in 2022, then soared by 403.28% to $231332.0 in 2023, then soared by 110.41% to $486748.0 in 2024, then soared by 38.48% to $674036.0 in 2025.
  • Its Receivables was $674036.0 in Q3 2025, compared to $295034.0 in Q2 2025 and $488243.0 in Q1 2025.